Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Koopman LA, Terp MG, Zom GG, Janmaat ML, Jacobsen K, Gresnigt-van den Heuvel E, Brandhorst M, Forssmann U, de Bree F, Pencheva N, Lingnau A, Zipeto MA, Parren PW, Breij EC, Ditzel HJ.
Koopman LA, et al. Among authors: ditzel hj.
JCI Insight. 2019 Nov 1;4(21):e128199. doi: 10.1172/jci.insight.128199.
JCI Insight. 2019.
PMID: 31600169
Free PMC article.